The role of transcatheter arterial embolization in patients with resectable hepatocellular carcinoma: A nation-wide, multicenter study

Yi Hsiang Huang, Chien Hung Chen, Ting-Tsung Chang, Shinn Cherng Chen, Shen Yung Wang, Pui Ching Lee, Hsuan Shu Lee, Pin Wen Lin, Guan Tarn Huang, Jin Chuan Sheu, Hong-Ming Tsai, Gar Yang Chau, Jen Huei Chiang, Wing Yiu Liu, Shou Dong Lee, Jaw Ching Wu

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Purpose: The role of transcatheter arterial embolization (TAE) for patients with resectable hepatocellular carcinoma (HCC) is controversial. Analyzing a cohort of nation-wide data can delineate the beneficial effect of TAE for those patients. Methods: From 1991 to 1995, 818 patients who had potentially resectable HCC from four medical centers in Taiwan were enrolled. Among them, 599 underwent curative resection, 157 received TAE and 62 received supportive treatment alone. The survivals among the three groups were compared. Results: The 5-year survival rates for patients who underwent surgery, TAE and supportive treatment were 43.6%, 25.6% and 3.7%, respectively. Surgery offered the best survival for those patients. TAE could also prolong survival as compared with supportive treatment (P = 0.0001). However, among patients who were in advanced tumor stage (Cancer and the Liver Italian Program (CLIP) score ≥ 2), no statistical difference in survival was noted between patients who underwent TAE or supportive treatment. In multivariate analysis, single tumor, serum albumin ≥ 3.5 g/dl, tumor size less than 5 cm, early-stage tumor (CLIP score = 0-1) and aggressive treatment including surgery and TAE were independent factors associated with a better survival. Conclusions: Surgery is superior to TAE for patients with resectable HCC. In patients who refuse surgery, TAE can be considered for selected patients whose tumors are in early stage.

Original languageEnglish
Pages (from-to)419-424
Number of pages6
JournalLiver International
Volume24
Issue number5
DOIs
Publication statusPublished - 2004 Oct 1

Fingerprint

Multicenter Studies
Hepatocellular Carcinoma
Survival
Neoplasms
Liver Neoplasms
Therapeutics
Taiwan
Serum Albumin
Multivariate Analysis
Survival Rate

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

Huang, Yi Hsiang ; Chen, Chien Hung ; Chang, Ting-Tsung ; Chen, Shinn Cherng ; Wang, Shen Yung ; Lee, Pui Ching ; Lee, Hsuan Shu ; Lin, Pin Wen ; Huang, Guan Tarn ; Sheu, Jin Chuan ; Tsai, Hong-Ming ; Chau, Gar Yang ; Chiang, Jen Huei ; Liu, Wing Yiu ; Lee, Shou Dong ; Wu, Jaw Ching. / The role of transcatheter arterial embolization in patients with resectable hepatocellular carcinoma : A nation-wide, multicenter study. In: Liver International. 2004 ; Vol. 24, No. 5. pp. 419-424.
@article{6a980f13b64545cb8a4e4fff031957a9,
title = "The role of transcatheter arterial embolization in patients with resectable hepatocellular carcinoma: A nation-wide, multicenter study",
abstract = "Purpose: The role of transcatheter arterial embolization (TAE) for patients with resectable hepatocellular carcinoma (HCC) is controversial. Analyzing a cohort of nation-wide data can delineate the beneficial effect of TAE for those patients. Methods: From 1991 to 1995, 818 patients who had potentially resectable HCC from four medical centers in Taiwan were enrolled. Among them, 599 underwent curative resection, 157 received TAE and 62 received supportive treatment alone. The survivals among the three groups were compared. Results: The 5-year survival rates for patients who underwent surgery, TAE and supportive treatment were 43.6{\%}, 25.6{\%} and 3.7{\%}, respectively. Surgery offered the best survival for those patients. TAE could also prolong survival as compared with supportive treatment (P = 0.0001). However, among patients who were in advanced tumor stage (Cancer and the Liver Italian Program (CLIP) score ≥ 2), no statistical difference in survival was noted between patients who underwent TAE or supportive treatment. In multivariate analysis, single tumor, serum albumin ≥ 3.5 g/dl, tumor size less than 5 cm, early-stage tumor (CLIP score = 0-1) and aggressive treatment including surgery and TAE were independent factors associated with a better survival. Conclusions: Surgery is superior to TAE for patients with resectable HCC. In patients who refuse surgery, TAE can be considered for selected patients whose tumors are in early stage.",
author = "Huang, {Yi Hsiang} and Chen, {Chien Hung} and Ting-Tsung Chang and Chen, {Shinn Cherng} and Wang, {Shen Yung} and Lee, {Pui Ching} and Lee, {Hsuan Shu} and Lin, {Pin Wen} and Huang, {Guan Tarn} and Sheu, {Jin Chuan} and Hong-Ming Tsai and Chau, {Gar Yang} and Chiang, {Jen Huei} and Liu, {Wing Yiu} and Lee, {Shou Dong} and Wu, {Jaw Ching}",
year = "2004",
month = "10",
day = "1",
doi = "10.1111/j.1478-3231.2004.0941.x",
language = "English",
volume = "24",
pages = "419--424",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "5",

}

Huang, YH, Chen, CH, Chang, T-T, Chen, SC, Wang, SY, Lee, PC, Lee, HS, Lin, PW, Huang, GT, Sheu, JC, Tsai, H-M, Chau, GY, Chiang, JH, Liu, WY, Lee, SD & Wu, JC 2004, 'The role of transcatheter arterial embolization in patients with resectable hepatocellular carcinoma: A nation-wide, multicenter study', Liver International, vol. 24, no. 5, pp. 419-424. https://doi.org/10.1111/j.1478-3231.2004.0941.x

The role of transcatheter arterial embolization in patients with resectable hepatocellular carcinoma : A nation-wide, multicenter study. / Huang, Yi Hsiang; Chen, Chien Hung; Chang, Ting-Tsung; Chen, Shinn Cherng; Wang, Shen Yung; Lee, Pui Ching; Lee, Hsuan Shu; Lin, Pin Wen; Huang, Guan Tarn; Sheu, Jin Chuan; Tsai, Hong-Ming; Chau, Gar Yang; Chiang, Jen Huei; Liu, Wing Yiu; Lee, Shou Dong; Wu, Jaw Ching.

In: Liver International, Vol. 24, No. 5, 01.10.2004, p. 419-424.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The role of transcatheter arterial embolization in patients with resectable hepatocellular carcinoma

T2 - A nation-wide, multicenter study

AU - Huang, Yi Hsiang

AU - Chen, Chien Hung

AU - Chang, Ting-Tsung

AU - Chen, Shinn Cherng

AU - Wang, Shen Yung

AU - Lee, Pui Ching

AU - Lee, Hsuan Shu

AU - Lin, Pin Wen

AU - Huang, Guan Tarn

AU - Sheu, Jin Chuan

AU - Tsai, Hong-Ming

AU - Chau, Gar Yang

AU - Chiang, Jen Huei

AU - Liu, Wing Yiu

AU - Lee, Shou Dong

AU - Wu, Jaw Ching

PY - 2004/10/1

Y1 - 2004/10/1

N2 - Purpose: The role of transcatheter arterial embolization (TAE) for patients with resectable hepatocellular carcinoma (HCC) is controversial. Analyzing a cohort of nation-wide data can delineate the beneficial effect of TAE for those patients. Methods: From 1991 to 1995, 818 patients who had potentially resectable HCC from four medical centers in Taiwan were enrolled. Among them, 599 underwent curative resection, 157 received TAE and 62 received supportive treatment alone. The survivals among the three groups were compared. Results: The 5-year survival rates for patients who underwent surgery, TAE and supportive treatment were 43.6%, 25.6% and 3.7%, respectively. Surgery offered the best survival for those patients. TAE could also prolong survival as compared with supportive treatment (P = 0.0001). However, among patients who were in advanced tumor stage (Cancer and the Liver Italian Program (CLIP) score ≥ 2), no statistical difference in survival was noted between patients who underwent TAE or supportive treatment. In multivariate analysis, single tumor, serum albumin ≥ 3.5 g/dl, tumor size less than 5 cm, early-stage tumor (CLIP score = 0-1) and aggressive treatment including surgery and TAE were independent factors associated with a better survival. Conclusions: Surgery is superior to TAE for patients with resectable HCC. In patients who refuse surgery, TAE can be considered for selected patients whose tumors are in early stage.

AB - Purpose: The role of transcatheter arterial embolization (TAE) for patients with resectable hepatocellular carcinoma (HCC) is controversial. Analyzing a cohort of nation-wide data can delineate the beneficial effect of TAE for those patients. Methods: From 1991 to 1995, 818 patients who had potentially resectable HCC from four medical centers in Taiwan were enrolled. Among them, 599 underwent curative resection, 157 received TAE and 62 received supportive treatment alone. The survivals among the three groups were compared. Results: The 5-year survival rates for patients who underwent surgery, TAE and supportive treatment were 43.6%, 25.6% and 3.7%, respectively. Surgery offered the best survival for those patients. TAE could also prolong survival as compared with supportive treatment (P = 0.0001). However, among patients who were in advanced tumor stage (Cancer and the Liver Italian Program (CLIP) score ≥ 2), no statistical difference in survival was noted between patients who underwent TAE or supportive treatment. In multivariate analysis, single tumor, serum albumin ≥ 3.5 g/dl, tumor size less than 5 cm, early-stage tumor (CLIP score = 0-1) and aggressive treatment including surgery and TAE were independent factors associated with a better survival. Conclusions: Surgery is superior to TAE for patients with resectable HCC. In patients who refuse surgery, TAE can be considered for selected patients whose tumors are in early stage.

UR - http://www.scopus.com/inward/record.url?scp=16344390827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16344390827&partnerID=8YFLogxK

U2 - 10.1111/j.1478-3231.2004.0941.x

DO - 10.1111/j.1478-3231.2004.0941.x

M3 - Article

C2 - 15482337

AN - SCOPUS:16344390827

VL - 24

SP - 419

EP - 424

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 5

ER -